← All trials
NCT06844500
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 23, 2025
- Primary completion
- Dec 31, 2025
- Completion date
- May 31, 2027
- First posted
- Feb 25, 2025
- Last posted
- Aug 27, 2025
- Enrollment
- 359
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of AntwerpLead sponsor
- ace africaCollaborator
- PENTA FoundationCollaborator
- University of AntwerpSponsor investigator
- University of KinshasaCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- University of AntwerpOfficial
- Bavarian NordicCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.